Get the Stockscreener App
1.58
11.27%
0.16
Pre-market:
1.61
0.03
+1.90%
Neuronetics Inc stock is traded at $1.58, with a volume of 3.04M.
It is up +11.27% in the last 24 hours and up +8.97% over the past month.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
See More
Previous Close:
$1.42
Open:
$1.5
24h Volume:
3.04M
Relative Volume:
1.46
Market Cap:
$109.94M
Revenue:
$149.16M
Net Income/Loss:
$-39.14M
P/E Ratio:
-2.6439
EPS:
-0.5976
Net Cash Flow:
$-21.18M
1W Performance:
+13.67%
1M Performance:
+8.97%
6M Performance:
-42.12%
1Y Performance:
-57.98%
1-Day Range:
$1.49
$1.61
1-Week Range:
$1.3401
$1.61
52-Week Range:
$0.80
$4.8495
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
1.58 | 98.80M | 149.16M | -39.14M | -21.18M | -0.5976 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Neuronetics to report fourth quarter 2025 results March 17 - MSN
How The Neuronetics (STIM) Investment Story Is Reset As Analysts Rework Valuation Assumptions - Yahoo Finance
Neuronetics (NASDAQ:STIM) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Neuronetics CFO Steven Pfanstiel to depart; company begins search for successor - MSN
Free cash flow per share of Neuronetics, Inc. – MUN:NRC - TradingView
Neuronetics Stock Drops 2.8% Amid Analyst Downgrades - National Today
Neuronetics (NASDAQ:STIM) Trading Down 2.8%Here's What Happened - MarketBeat
Q3 2025 Neuronetics Inc Earnings Call Transcript - GuruFocus
Neuronetics CFO Steven Pfanstiel to Depart in May - MyChesCo
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners - The Manila Times
Neuronetics IncPolicy Expanded to Pmhnps i - Moomoo
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include ... - nrtoday.com
Neuronetics, Inc. Highlights Optum/UHC/UBH TMS Policy Expansion Enabling PMHNPs To Deliver NeuroStar Therapy Across 26 States And Washington D.C - marketscreener.com
[EFFECT] Neuronetics, Inc. SEC Filing - Stock Titan
Neuronetics (STIM) price target increased by 44.44% to 4.42 - MSN
Why is STIM stock rallying 16% after-hours? - MSN
Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan - Sahm
Malvern’s Neuronetics faces sale pressure from top shareholder - MSN
Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan - Benzinga
Neuronetics (NASDAQ: STIM) to vote on board, pay and 2026 equity plan - Stock Titan
Major Neuronetics (STIM) holder presses Board to review TMS business - Stock Titan
STIM DEFA14A & SEC Filings - Yahoo Finance Australia
Top shareholder says Neuronetics has 'chronically underperformed,’ pushes sale review - The Business Journals
Neuronetics responds to shareholder letter on valuation By Investing.com - Investing.com India
Neuronetics responds to shareholder letter on valuation - Investing.com
Neuronetics Comments on Letter from Pointillist Family Office - The Manila Times
Neuronetics Announces Chief Financial Officer Transition - National Today
Neuronetics CFO Transition Announced; Company Reaffirms 2026 Financial Guidance and Focus on NeuroStar Advanced Therapy 1 - Minichart
Why Is STIM Stock Rallying 16% After-Hours? - Stocktwits
Neuronetics CFO Steven Pfanstiel to depart in May By Investing.com - Investing.com Canada
Aug Outlook: Is Neuronetics Inc stock a buy or sellEarnings Beat & Community Trade Idea Sharing Platform - baoquankhu1.vn
Neuronetics (STIM) CFO Steven Pfanstiel to Step Down - GuruFocus
STIM Maintains FY26 Financial Outlook with Key Projections - GuruFocus
Neuronetics (STIM) Reaffirms Financial Guidance Amid New Announcement - GuruFocus
Neuronetics (STIM) Shareholder Pushes for Strategic Alternatives Review - GuruFocus
Neuronetics largest shareholder pushes for strategic review By Investing.com - Investing.com Australia
Neuronetics Announces Planned Departure of CFO Steven Pfanstiel and Leadership Transition - citybiz
Neuronetics Announces CFO Transition and Reaffirms 2026 Outlook - TipRanks
Neuronetics Inc. announced that its Chief Financial Officer and Treasurer, Steven E. Furlansteir, has decided to step down. - Bitget
Neuronetics Inc initiates workforce reduction impacting up to 5% of employees - marketscreener.com
Neuronetics announces chief financial officer transition - marketscreener.com
Neuronetics Inc Initiates Workforce Reduction Impacting Up To 5% Of Employees - TradingView — Track All Markets
Neuronetics Announces CFO Exit, Reaffirms Financial Guidance - marketscreener.com
Neuronetics, Inc. Announces Departure of CFO Steven E. Pfanstiel, Confirms Financial Guidance - Quiver Quantitative
CFO exit and cost cuts at Neuronetics (NASDAQ: STIM) 2026 - Stock Titan
Neuronetics, Inc. Announces to Depart Steven E. Pfanstiel as Executive Vice President and Treasurer, Effective May 1, 2026 - marketscreener.com
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):